BOSTON SCIENTIFIC CORP (1BSX.MI) Stock Fundamental Analysis
Europe - BIT:1BSX - US1011371077 - Common Stock
85.8 EUR
+2.8 (+3.37%)
We assign a fundamental rating of 5 out of 10 to 1BSX. 1BSX was compared to 62 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of 1BSX get a neutral evaluation. Nothing too spectacular is happening here. 1BSX is valued quite expensively, but it does show have an excellent growth rating. This makes 1BSX very considerable for growth investing!
1. Profitability
1.1 Basic Checks
1BSX had positive earnings in the past year.
In the past year 1BSX had a positive cash flow from operations.
1BSX had positive earnings in 4 of the past 5 years.
1BSX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
1BSX has a Return On Assets of 6.03%. This is in the better half of the industry: 1BSX outperforms 69.84% of its industry peers.
1BSX's Return On Equity of 11.17% is fine compared to the rest of the industry. 1BSX outperforms 69.84% of its industry peers.
1BSX's Return On Invested Capital of 7.66% is fine compared to the rest of the industry. 1BSX outperforms 66.67% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1BSX is below the industry average of 8.76%.
The 3 year average ROIC (6.54%) for 1BSX is below the current ROIC(7.66%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROIC | 7.66% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
1.3 Margins
The Profit Margin of 1BSX (13.54%) is better than 79.37% of its industry peers.
1BSX's Profit Margin has declined in the last couple of years.
1BSX has a Operating Margin of 18.69%. This is amongst the best in the industry. 1BSX outperforms 80.95% of its industry peers.
1BSX's Operating Margin has been stable in the last couple of years.
1BSX's Gross Margin of 68.30% is fine compared to the rest of the industry. 1BSX outperforms 77.78% of its industry peers.
In the last couple of years the Gross Margin of 1BSX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% |
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
2. Health
2.1 Basic Checks
1BSX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
1BSX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for 1BSX has been increased compared to 5 years ago.
The debt/assets ratio for 1BSX is higher compared to a year ago.
2.2 Solvency
1BSX has an Altman-Z score of 5.39. This indicates that 1BSX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.39, 1BSX belongs to the top of the industry, outperforming 84.13% of the companies in the same industry.
1BSX has a debt to FCF ratio of 3.33. This is a good value and a sign of high solvency as 1BSX would need 3.33 years to pay back of all of its debts.
The Debt to FCF ratio of 1BSX (3.33) is better than 77.78% of its industry peers.
1BSX has a Debt/Equity ratio of 0.50. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of 1BSX (0.50) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Altman-Z | 5.39 |
ROIC/WACC0.94
WACC8.16%
2.3 Liquidity
1BSX has a Current Ratio of 1.37. This is a normal value and indicates that 1BSX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.37, 1BSX perfoms like the industry average, outperforming 47.62% of the companies in the same industry.
1BSX has a Quick Ratio of 1.37. This is a bad value and indicates that 1BSX is not financially healthy enough and could expect problems in meeting its short term obligations.
1BSX has a Quick ratio of 0.82. This is comparable to the rest of the industry: 1BSX outperforms 41.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 |
3. Growth
3.1 Past
1BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.91%, which is quite impressive.
Measured over the past years, 1BSX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.56% on average per year.
The Revenue has grown by 21.45% in the past year. This is a very strong growth!
The Revenue has been growing by 9.30% on average over the past years. This is quite good.
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
3.2 Future
1BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.40% yearly.
Based on estimates for the next years, 1BSX will show a quite strong growth in Revenue. The Revenue will grow by 12.12% on average per year.
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 35.45, 1BSX can be considered very expensive at the moment.
1BSX's Price/Earnings ratio is in line with the industry average.
1BSX is valuated rather expensively when we compare the Price/Earnings ratio to 26.89, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 29.20, the valuation of 1BSX can be described as expensive.
1BSX's Price/Forward Earnings is on the same level as the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.99. 1BSX is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.45 | ||
| Fwd PE | 29.2 |
4.2 Price Multiples
1BSX's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. 1BSX is more expensive than 61.90% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 1BSX is valued a bit cheaper than the industry average as 68.25% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.63 | ||
| EV/EBITDA | 32.2 |
4.3 Compensation for Growth
1BSX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
1BSX has a very decent profitability rating, which may justify a higher PE ratio.
1BSX's earnings are expected to grow with 15.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.77
PEG (5Y)3.71
EPS Next 2Y16.93%
EPS Next 3Y15.51%
5. Dividend
5.1 Amount
1BSX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIT:1BSX (10/20/2025, 7:00:00 PM)
85.8
+2.8 (+3.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners93.27%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap127.13B
Revenue(TTM)18.49B
Net Income(TTM)2.50B
Analysts86.34
Price Target108.53 (26.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.53%
Min EPS beat(2)2.49%
Max EPS beat(2)10.56%
EPS beat(4)4
Avg EPS beat(4)6.23%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.12%
EPS beat(12)11
Avg EPS beat(12)5.14%
EPS beat(16)15
Avg EPS beat(16)4.28%
Revenue beat(2)2
Avg Revenue beat(2)1.7%
Min Revenue beat(2)0.97%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)2.15%
Min Revenue beat(4)0.97%
Max Revenue beat(4)3.16%
Revenue beat(8)8
Avg Revenue beat(8)2.1%
Revenue beat(12)11
Avg Revenue beat(12)2.01%
Revenue beat(16)12
Avg Revenue beat(16)1.41%
PT rev (1m)1.38%
PT rev (3m)2.32%
EPS NQ rev (1m)-0.04%
EPS NQ rev (3m)2.33%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)2.17%
Revenue NQ rev (1m)0.22%
Revenue NQ rev (3m)2.28%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)2.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 35.45 | ||
| Fwd PE | 29.2 | ||
| P/S | 8.03 | ||
| P/FCF | 42.63 | ||
| P/OCF | 34.67 | ||
| P/B | 6.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | 32.2 |
EPS(TTM)2.42
EY2.82%
EPS(NY)2.94
Fwd EY3.42%
FCF(TTM)2.01
FCFY2.35%
OCF(TTM)2.48
OCFY2.88%
SpS10.69
BVpS12.95
TBVpS-1.69
PEG (NY)1.77
PEG (5Y)3.71
Graham Number26.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.03% | ||
| ROE | 11.17% | ||
| ROCE | 9.51% | ||
| ROIC | 7.66% | ||
| ROICexc | 7.77% | ||
| ROICexgc | 26.52% | ||
| OM | 18.69% | ||
| PM (TTM) | 13.54% | ||
| GM | 68.3% | ||
| FCFM | 18.84% |
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.54%
ROIC(5y)5.68%
ROICexc(3y)6.7%
ROICexc(5y)5.9%
ROICexgc(3y)22.68%
ROICexgc(5y)19.43%
ROCE(3y)8.12%
ROCE(5y)7.05%
ROICexgc growth 3Y8.56%
ROICexgc growth 5Y6.81%
ROICexc growth 3Y4.36%
ROICexc growth 5Y5.23%
OM growth 3Y0.33%
OM growth 5Y1.13%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.3%
GM growth 5Y-0.65%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 3.33 | ||
| Debt/EBITDA | 2.33 | ||
| Cap/Depr | 60.84% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 89.77% | ||
| Profit Quality | 139.08% | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 0.82 | ||
| Altman-Z | 5.39 |
F-Score5
WACC8.16%
ROIC/WACC0.94
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.91%
EPS 3Y15.48%
EPS 5Y9.56%
EPS Q2Q%20.97%
EPS Next Y19.98%
EPS Next 2Y16.93%
EPS Next 3Y15.51%
EPS Next 5Y14.4%
Revenue 1Y (TTM)21.45%
Revenue growth 3Y12.1%
Revenue growth 5Y9.3%
Sales Q2Q%22.84%
Revenue Next Year19.71%
Revenue Next 2Y15.31%
Revenue Next 3Y13.67%
Revenue Next 5Y12.12%
EBIT growth 1Y26.44%
EBIT growth 3Y12.47%
EBIT growth 5Y10.54%
EBIT Next Year35.51%
EBIT Next 3Y19.85%
EBIT Next 5Y17.06%
FCF growth 1Y131.03%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y101.7%
OCF growth 3Y22.44%
OCF growth 5Y13.34%
BOSTON SCIENTIFIC CORP / 1BSX.MI FAQ
What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 1BSX.MI.
What is the valuation status of BOSTON SCIENTIFIC CORP (1BSX.MI) stock?
ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (1BSX.MI). This can be considered as Overvalued.
What is the profitability of 1BSX stock?
BOSTON SCIENTIFIC CORP (1BSX.MI) has a profitability rating of 6 / 10.
What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (1BSX.MI) is 35.45 and the Price/Book (PB) ratio is 6.62.
Can you provide the financial health for 1BSX stock?
The financial health rating of BOSTON SCIENTIFIC CORP (1BSX.MI) is 5 / 10.